Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

O-2050

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
O-2050
Identifiers
  • (6aR,10aR)-3-(1-Methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
CAS Number
PubChemCID
ChemSpider
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC23H31NO4S
Molar mass417.56 g·mol−1
3D model (JSmol)
  • CC1=CC[C@@H]2[C@@H](C1)c3c(cc(cc3OC2(C)C)CC#CCCCNS(=O)(=O)C)O
  • InChI=1S/C23H31NO4S/c1-16-10-11-19-18(13-16)22-20(25)14-17(15-21(22)28-23(19,2)3)9-7-5-6-8-12-24-29(4,26)27/h10,14-15,18-19,24-25H,6,8-9,11-13H2,1-4H3/t18-,19-/m1/s1
  • Key:DJTGGIYZQHHLGJ-RTBURBONSA-N
 ☒NcheckY (what is this?)

O-2050 is a drug that is a classical cannabinoid derivative, which acts as anantagonist for theCB1receptor. This gives it an advantage in research over many commonly usedcannabinoid antagonists, such asrimonabant, which at higher doses act asinverse agonists at CB1 as well as showing off-target effects. However, while O-2050 acts as a silent antagonistin vitro, some testsin vivo have suggested it may show agonist activity under certain circumstances.[1][2][3][4][5][6]

See also

[edit]

References

[edit]
  1. ^Martin BR, Stephenson LA, Pertwee RG, Breivogel CS, Williams W, Mahadevan A, Razdan RK (2002)."Agonists and silent antagonists in a series of cannabinoid sulfonamides"(PDF).12th Annual Symposium on the Cannabinoids.
  2. ^US 7279500, Martin, Billy R.; Razdan, Raj K. & Pertwee, Roger G, "Sulfonamide cannabinoid agonists and antagonists", published 2007-10-09, assigned toVirginia Commonwealth University 
  3. ^Gardner A, Mallet PE (January 2006). "Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'".European Journal of Pharmacology.530 (1–2):103–6.doi:10.1016/j.ejphar.2005.11.032.PMID 16380113.
  4. ^Higuchi S, Irie K, Mishima S, Araki M, Ohji M, Shirakawa A, et al. (2010)."The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice".Journal of Pharmacological Sciences.112 (3):369–72.doi:10.1254/jphs.09326sc.PMID 20168044.
  5. ^Higuchi S, Ohji M, Araki M, Furuta R, Katsuki M, Yamaguchi R, et al. (January 2011). "Increment of hypothalamic 2-arachidonoylglycerol induces the preference for a high-fat diet via activation of cannabinoid 1 receptors".Behavioural Brain Research.216 (1):477–80.doi:10.1016/j.bbr.2010.08.042.PMID 20817042.S2CID 29756189.
  6. ^Wiley JL, Breivogel CS, Mahadevan A, Pertwee RG, Cascio MG, Bolognini D, et al. (January 2011)."Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist".European Journal of Pharmacology.651 (1–3):96–105.doi:10.1016/j.ejphar.2010.10.085.PMC 3034309.PMID 21114999.
Phytocannabinoids
(comparison)
Cannabibutols
Cannabichromenes
Cannabicyclols
Cannabidiols
Cannabielsoins
Cannabigerols
Cannabiphorols
Cannabinols
Cannabitriols
Cannabivarins
Delta-8-tetrahydrocannabinols
Delta-9-tetrahydrocannabinols
Delta-10-Tetrahydrocannabinols
Miscellaneous cannabinoids
Active metabolites
Endocannabinoids
Synthetic
cannabinoid
receptor
agonists /
neocannabinoids
Classical cannabinoids
(dibenzopyrans)
Non-classical
cannabinoids
Adamantoylindoles
Benzimidazoles
Benzoylindoles
Cyclohexylphenols
Eicosanoids
Indazole-3-
carboxamides
Indole-3-carboxamides
Indole-3-carboxylates
Naphthoylindazoles
Naphthoylindoles
Naphthoylpyrroles
Naphthylmethylindenes
Naphthylmethylindoles
Phenylacetylindoles
Pyrazolecarboxamides
Tetramethylcyclo-
propanoylindazoles
Tetramethylcyclo-
propanoylindoles
Others
AllostericCBRTooltip Cannabinoid receptorligands
Endocannabinoid
enhancers
(inactivation inhibitors)
Anticannabinoids
(antagonists/inverse
agonists/antibodies)
Stub icon

Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=O-2050&oldid=1268801296"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp